IMFINZI Overview

Imfinzi is a medicine used to treat a type of lung cancer called non-small cell lung cancer (NSCLC).

Imfinzi is used in adult patients with advanced cancer that cannot be removed by surgery but is not getting worse after treatment with radiation and platinum-based chemotherapy (medicines to treat cancer). Imfinzi is used specifically when the tumour produces a protein known as PD-L1.

Imfinzi contains the active substance durvalumab.


Imfinzi is given as an infusion (drip) into a vein every 2 weeks. The dose is calculated based on the patient’s body weight. Treatment should continue for as long as the patient benefits from it or for up to 1 year. Treatment may be paused or stopped permanently if the patient experiences severe side effects.

Imfinzi can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in treating cancer.

For more information about using Imfinzi, see the package leaflet or contact your doctor or pharmacist

The active substance in Imfinzi, durvalumab, is a monoclonal antibody, a type of protein designed to recognise and attach to a protein called ‘programmed death-ligand 1’ (PD-L1), which is present on the surface of many cancer cells.

PD-L1 acts to switch off immune cells that would otherwise attack the cancer cells. By attaching to PD- L1 and blocking its effects, Imfinzi increases the ability of the immune system to attack the cancer cells and thereby slow down the progression of the disease.

Imfinzi has been shown to be more effective than placebo (a dummy treatment) at prolonging the time patients with advanced non-small cell lung cancer lived without their disease getting worse. In one main study of 713 patients, patients given Imfinzi lived on average for around 17 months without their disease getting worse, compared with 6 months for those given placebo.

Preliminary results also indicated that patients given Imfinzi lived longer overall, compared with patients on placebo, though longer monitoring would be needed to confirm the extent of the benefit.

Imfinzi was shown to improve the length of time patients with advanced NSCLC lived without their disease getting worse, and this was considered important for these patients, who have few treatment options. The use of Imfinzi is restricted to patients whose tumours produce PD-L1, since a clear benefit was only shown in this group of patients. Side effects with Imfinzi were considered manageable, and its safety profile acceptable and in line with that of similar medicines.

The European Medicines Agency therefore decided that Imfinzi’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imfinzi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Imfinzi are continuously monitored. Side effects reported with Imfinzi are carefully evaluated and any necessary action taken to protect patients.


What are the risks associated with Imfinzi?

The most common side effects with Imfinzi (which may affect more than 1 in 5 people) are cough, nose and throat infections, and rash. The most common serious side effect (which may affect up to 1 in 10 people) is pneumonia (infection of the lungs).


Owner of copyright and other intellectual property rights to European Medicines Agency

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Find more drugs

CAPRELSA®( vandetanib )

Drug CAPRELSA® vandetanib Caprelsa Overview This is a summary of the European public assessment report (EPAR)

MEKINIST® (trametinib)

Drug MEKINIST® trametinib Mekinist Overview Mekinist is a cancer medicine used to treat adults whose cancer


Drug PEMETREXED ACCORD® pemetrexed Pemetrexed Accord Overview This is a summary of the European public assessment report (EPAR)


At one place know the best information on various cancer drugs and common symptoms associated.

CANKADO’s PRO-react Onco helps efficient patient physician communication in the treatment phase.


© 2021 Cancer.Cankado. All rights Reserved

CANKADO is approved as an active Class I medical device within the European Union (registration number DE/CA59/11976/2017) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B.

Auto Translate »

CANKADO processes information about your visit on this website using cookies. These are required to ensure the correct functionality of the homepage, to improve its performance and our third-party services. These services cannot be used without your consent.